

## **Product datasheet for TL305509V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **CD47 Human shRNA Lentiviral Particle (Locus ID 961)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** CD47 Human shRNA Lentiviral Particle (Locus ID 961)

Locus ID: 96°

Synonyms: IAP; MER6; OA3

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CD47 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001025079, NM 001025080, NM 001777, NM 198793, NM 001777.1, NM 001777.2,

NM 001777.3, NM 001025079.1, BC037306, BC037306.1, BC010016, BC012884, BC042889,

BC045593, BC053959, NM 001777.4, NM 198793.3

UniProt ID: Q08722

**Summary:** This gene encodes a membrane protein, which is involved in the increase in intracellular

calcium concentration that occurs upon cell adhesion to extracellular matrix. The encoded protein is also a receptor for the C-terminal cell binding domain of thrombospondin, and it may play a role in membrane transport and signal transduction. This gene has broad tissue distribution, and is reduced in expression on Rh erythrocytes. Alternatively spliced transcript

variants have been found for this gene. [provided by RefSeq, Jul 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).